Systematix

Institutional Equities

NMDC 19 August 2025

Consistent volume growth to drive rerating

NMDC reported 1QFY26 EBITDA of Rs 24.8bn (+6%/+21% YoY/QoQ), 4% below our estimate. Increase in EBITDA was majorly driven by reduced other expenditure, employee benefits and lower than expected realizations during the quarter. Iron ore production and sales for the quarter were 12mt (+30.6%/-9.6% YoY/QoQ), and 11.5mt (+14.3%/-9.1% YoY/QoQ), respectively. Realizations averaged Rs 5,353/t in 1Q, flat/+6.9% YoY/QoQ, 5% below our estimate of Rs 5,634/t. EBITDA margin during the quarter was 36.8% compared to 29.3% in 4QFY25 and 43.2% in 1QFY25. Cost of production excl. selling expenses and royalty stood at Rs 1,263/t (+34%/-15% YoY/QoQ). Employee costs per ton decreased to Rs 357/t this quarter versus Rs 432/t in 4QFY25. We upgrade NMDC to BUY with a revised TP of Rs 83/share based on 5.5x FY27E EV/EBITDA, implying an upside of 20% from CMP.

Valuation and view: NMDC has reported robust volumes this year aligning closer to the management's aspiration to deliver 55mt volumes. Over the April to July FY26 period, NMDC has posted 33% and 14% YoY growth in iron ore production and sales, respectively. Further, NMDC commenced pellet exports in 4Q, recording notable increase in topline contribution (8% in 1QFY26 versus 1% CPLY) and turned profitable this quarter. The company also revised iron ore prices by 7%-8% MoM for August deliveries. We revise our FY26/FY27 EBITDA estimate higher by 12%/13% based on 14% and 8% sales volume growth in FY26 and FY27, respectively. We value NMDC at 5.5x FY27E EV/EBITDA with a revised target price of Rs 83/share, implying an upside of 20% from CMP. The company is progressing towards its 100mt capacity target with a revised estimated outlay of Rs 720bn. NMDC spent Rs 34bn capex in FY25 and expects over Rs 100bn in capex spending for the next two years. Upgrade to BUY.

Risks and re-rating levers: Weak global iron ore pricing, sluggish volumes, or extended monsoons are key risks. Demonstration of continued monthly volume growth is likely to be a rerating driver.

RESULT UPDATE Sector: Metals Rating: BUY CMP: Rs 69 Target Price: Rs 83


Stock Info	
Sensex/Nifty	81,303/ 24,917
Bloomberg	NMDC IN
Equity shares (mn)	8,792
52-wk High/Low	Rs 82.8/59.5
Face value	Rs 1
M-Cap	Rs 610bn/USD 7.0bn

	The state of the s							
Y/E Mar	FY25	FY26E	FY27E					
Sales	239.1	305.0	341.4					
EBITDA	85.7	110.0	121.9					
PAT	69.6	77.6	79.8					
EPS (Rs)	7.9	8.8	9.1					
PE (x)	8.8	7.9	7.7					
EV/EBITDA (x)	6.4	5.0	4.5					
RoE (%)	25%	24%	21%					
RoCE (%)	28%	30%	26%					
Dividend yield (%)	4.7%	2.5%	2.6%					

Shareholding Pattern (%)

Jun'25	Mar'25	Dec'24
60.8	60.8	60.8
0	0.0	0.0
12.2	11.7	12.1
14.5	15.1	14.5
12.5	12.4	12.6
	60.8 0 12.2 14.5	60.8 60.8 0 0.0 12.2 11.7 14.5 15.1

Stock Performance (1-year)



Shweta Dikshit

shwetadikshit@systematixgroup.in +91 22 6704 8042

Umang Saraiya

umangsaraiya@systematixgroup.in +91 22 6704 8019

NMDC 19 August 2025

Exhibit 1: Quarterly snapshot


(Rs bn)	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Net revenues	54	49	66	70	67
YoY change (%)					24%
QoQ change (%)					-4%
Expenditure	31	35	42	50	43
EBITDA	23	14	24	21	25
YoY change (%)					6%
QoQ change (%)					21%
EBITDA Margin (%)	43	28	36	29	37
Adj. PAT	20	12	19	15	20
YoY change (%)					0%
QoQ change (%)					33%

Exhibit 2: NMDC's realisation trend for lumps and fines

8 Par 2 Par

Source: Company, Systematix Institutional Research

Exhibit 3: In comparison to standard iron ore pricing benchmarks




Source: Company, Systematix Institutional Research

Exhibit 4: Discount to international prices has contracted




Source: Company, Systematix Institutional Research

Exhibit 5: Dispatch volumes have picked up YoY



Source: Company, Systematix Institutional Research

Exhibit 6: YoY/QoQ change in quarterly dispatch volumes



Source: Company, Systematix Institutional Research

Exhibit 7: Quarterly average NSR trend





Exhibit 8: YoY/QoQ change in quarterly average NSR

150% 88% 25% -38% -100% 1QFY25 **2QFY25** 3QFY25 1QFY21 1QFY22 LQFY23 3QFY23 1QFY24 3QFY24 20FY22 4QFY22 **2QFY24** 4QFY24


Source: Company, Systematix Institutional Research

Exhibit 9: EBITDA/t improved QoQ




Source: Company, Systematix Institutional Research

Exhibit 10: YoY change in quarterly EBITDA/t



Source: Company, Systematix Institutional Research

Exhibit 11: Cost of production



Source: Company, Systematix Institutional Research

Exhibit 12: YoY change in CoP



Source: Company, Systematix Institutional Research

Exhibit 13: Annual dispatch expected to pick up





Exhibit 14: Revenue growth to be in line with volumes

69% 80% 438 30% 33% 350 28% 40% 12% 263 0% 175 -40% 88 -80% FY27E FY25 FY21 FY24 Revenue (Rs bn) YoY Growth (RHS)

Exhibit 15: EBITDA trend



Source: Company, Systematix Institutional Research

Source: Company, Systematix Institutional Research

Exhibit 16: EBITDA/t





Exhibit 17: Profit After Tax



Source: Company, Systematix Institutional Research

Source: Company, Systematix Institutional Research

Exhibit 18: RoE and RoCE trend






Exhibit 19: Working capital cycle



Source: Company, Systematix Institutional Research

Exhibit 20: FCF turns negative with rising capex



Source: Company, Systematix Institutional Research

Exhibit 21: Key assumptions

The Life Cy assumptions								
	FY22	FY23	FY24	FY25	FY26E	FY27E		
Iron ore production volume (mt)	41	38	45	44	51	55		
Iron ore sales volume (mt)	41	38	45	44	51	55		
Avg. iron ore realization (USD/t)	78	48	54	64	65	67		
Avg. iron ore realization (Rs/t) (Incl. Royalty)	5,927	3,781	4,543	5,368	5,520	5,686		
EBITDA/tonne (Rs/t)	3,096	1,582	1,634	1,928	2,171	2,228		
EBITDA/tonne (USD/t)	41	20	20	23	26	26		
Cost/tonne (USD/t)	37	28	35	41	40	41		

Source: Systematix Institutional Research

Exhibit 22: NMDC Valuation: EV/EBITDA method (FY27E)

	Discount	Particulars	Multiple	Ent. value	Per share
	(%)	(Rs bn)	(x)	(Rs bn)	(Rs)
EBITDA		121.9	5.5	670	76
Net cash (FY25)		63	1.00	63	7
Target price per share				83	

Source: Systematix Institutional Research

Exhibit 23: Revised estimates

(Rs bn)	Previous		Revised		% Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	283	308	305	341	8%	11%
EBITDA	98	108	110	122	12%	13%
PAT	70	72	78	80	11%	11%
Avg. iron ore realization (USD/t)	64	63	65	67	2%	6%
Iron ore sales volume (mt)	48.0	51.8	50.7	54.7	6%	6%

FINANCIALS (CONSOLIDATED)

Profit & Loss Statement

YE: Mar (Rs bn)	FY23	FY24	FY25	FY26E	FY27E
Net Sales	177	213	239	305	341
Expenditure	116	140	153	195	220
EBITDA	61	73	86	110	122
Depreciation	3	4	4	7	11
EBIT	57	69	81	103	111
Interest and other income	7	13	14	4	(0)
Exceptionals	(12)	3	-	-	-
PBT	76	80	96	108	111
Taxes	21	24	26	30	31
Adj. PAT	64	54	70	78	80
No of shares	2,931	2,931	8,792	8,792	8,792
Adj. EPS	21.7	18.3	7.9	8.8	9.1

Source: Company, Systematix Institutional Research

Balance Sheet

Daidinec Sinces					
YE: Mar (Rs bn)	FY23	FY24	FY25	FY26E	FY27E
Equity capital	3	3	9	9	9
Reserves and surplus	223	254	288	347	408
Net worth	226	257	297	356	416
Debt	21	34	38	48	58
Other liabilities	23	33	35	35	35
Total liabilities and equity	300	357	410	494	602
Inventories	27	28	26	36	39
Debtors	44	35	77	53	56
Cash and bank	71	124	101	99	99
Loans and advances	5	3	3	3	3
Total current assets	176	213	234	217	223
Net block	30	25	26	70	109
CWIP	20	32	47	104	167
Investments	9	10	10	10	10
Current liabilities	59	84	97	111	124
Provisions	14	16	16	16	16
Net deferred tax	3	3	3	3	(7)
Other assets	21	33	39	42	42
Total assets	300	357	410	494	602
C			1.		

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs bn)	FY23	FY24	FY25	FY26E	FY27E
PBT	76	80	91	108	111
Add: Depreciation	3	4	4	7	11
Add: Interest	(5)	(10)	(12)	(4)	0
Less: taxes paid	(21)	(18)	(25)	(30)	(31)
Add: Other adjustments	1	1	2	0	0
Less: WC changes	(36)	19	(43)	20	(4)
Total OCF	18	74	19	99	87
OCF w/o WC changes	55	55	62	80	91
Capital expenditure	(12)	(18)	(32)	(107)	(113)
Change in investments	0	(0)	(0)	-	-
Interest/Dividend Recd	6	10	12	4	(0)
Total ICF	2	(61)	3	(102)	(113)
Free Cash Flows	6	55	(13)	(7)	(26)
Dividend payment	(11)	(25)	(25)	(19)	(19)
Change in borrowings	(1)	(0)	(2)	-	-
Buyback	-	-	-	-	-
Total Financing CF	(21)	(13)	(22)	1	26
Net change in cash	(0)	0	(0)	(2)	(0)
Opening cash & CE	1	1	1	1	(1)
Closing cash & CE	0.9300	1.0939	0.8483	(0.8101)	(0.9604)

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY23	FY24	FY25	FY26E	FY27E
YoY growth in Revenue	-32%	21%	12%	28%	12%
YoY growth in EBITDA	-52%	20%	17%	28%	11%
YoY growth in Net income	-33%	-16%	30%	12%	3%
EBITDA margin	34%	34%	36%	36%	36%
PAT margin	36%	25%	29%	25%	23%
ROE	31%	22%	25%	24%	21%
ROCE	26%	27%	28%	30%	26%
Net debt to equity (x)	(0.22)	(0.35)	(0.21)	(0.14)	(0.10)
Per share numbers (Rs)					
Reported earnings	21.7	18.3	7.9	8.8	9.1
Dividend	6.6	6.6	3.3	1.8	1.8
Free cash	2.0	18.9	(1.5)	(0.8)	(2.9)
Book value	77	88	34	40	47
Valuations (x)					
P/E	3.2	3.8	8.8	7.9	7.7
EV/EBITDA	9.1	7.5	6.4	5.0	4.5
EV to sales	3.1	2.6	2.3	1.8	1.6
P/B	2.7	2.4	2.1	1.7	1.5

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, Shweta Dikshit, Umang Saraiya; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Systematix Shares and Stocks (India) Limited (SSSIL) or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

- II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:
 - 1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
 - 2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
 - 3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
 - 4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
 - 5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
 - 6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
 - 7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
 - 8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
 - 9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.





Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell: grievance@systematixgroup.in

Details of Registration: CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH20000840 | AMFI: ARN - 64917